Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ashtead Technology confirms move to main market as H1 results impress

(Sharecast News) - Shares in AIM-listed Ashtead Technology jumped on Tuesday after the subsea tech group revealed a surge in both revenues and adjusted profits in the first half, as it confirmed plans to move to the Main Market. The firm, which provides tech solutions to the offshore energy sector, intends to apply for admission to the Main Market of the London Sock Exchange, with the move expected to happen on 6 October.

Chief executive Allan Pirie said the Main Market will give "greater liquidity and broader access to international investors", and provide an "excellent platform" for growth.

First-half results showed a 23.2% increase in revenues to £99.1m, driven by 22.7% in organic growth following the Seatronics and J2 Subsea businesses acquired in November 2024. Adjusted EBITDA was 19.7% higher than last year at £27.0m,.

Seatronics and J2 Subsea have added "significant scale to our business", Ashtead said, delivered higher operational synergies quicker than initially expected at the time of acquisition.

"The group has continued to deliver strong profitability and year-on-year growth despite some market and geopolitical headwinds during the period," Pirie said.

"While this business environment somewhat tempered activity and led to a slower seasonal ramp up of revenues through Q2, we have been able to continue to strengthen our business, execute on our long-term strategy and focus on driving enhanced quality of earnings."

Key projects delayed by customers during the first half have now begun, bolstering expectations for the latter part of the year.

The stock was up 12.1% at 585.5p by 0849 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.